Marksans Pharma [MARKSANS] vs Granules India [GRANULES] Detailed Stock Comparison
Marksans Pharma
NSE
Loading...
Granules India
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Marksans Pharma wins in 10 metrics, Granules India wins in 10 metrics, with 0 ties. Both stocks appear equally matched on key metrics.
View Metrics Details
Vital Metrics Comparison
| Metric | Marksans Pharma | Granules India | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 21.54 | 27.57 | Marksans Pharma |
| Price-to-Book Ratio | 3.06 | 3.55 | Marksans Pharma |
| Debt-to-Equity Ratio | 12.93 | 39.15 | Marksans Pharma |
| PEG Ratio | -0.63 | -1.67 | Granules India |
| EV/EBITDA | 15.22 | 15.64 | Marksans Pharma |
| Profit Margin (TTM) | 13.20% | 10.63% | Marksans Pharma |
| Operating Margin (TTM) | 12.42% | 14.70% | Granules India |
| EBITDA Margin (TTM) | 12.42% | 14.70% | Granules India |
| Return on Equity | 15.29% | 13.50% | Marksans Pharma |
| Return on Assets (TTM) | 11.75% | 8.02% | Marksans Pharma |
| Free Cash Flow (TTM) | $337.45M | $2.95B | Granules India |
| Dividend Yield | 0.62% | 0.30% | Marksans Pharma |
| 1-Year Return | -42.54% | -2.19% | Granules India |
| Price-to-Sales Ratio (TTM) | 2.85 | 2.93 | Marksans Pharma |
| Enterprise Value | $71.85B | $141.47B | Granules India |
| EV/Revenue Ratio | 2.71 | 3.14 | Marksans Pharma |
| Gross Profit Margin (TTM) | 57.77% | 64.84% | Granules India |
| Revenue per Share (TTM) | $59 | $186 | Granules India |
| Earnings per Share (Diluted) | $7.73 | $19.75 | Granules India |
| Beta (Stock Volatility) | 1.17 | -0.14 | Granules India |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Marksans Pharma vs Granules India Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Marksans Pharma | -0.08% | 1.31% | -3.75% | -35.83% | -28.57% | -45.34% |
| Granules India | 2.70% | 8.02% | 7.49% | 13.70% | 13.46% | -6.71% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Marksans Pharma | -42.54% | 252.44% | 210.98% | 57.62% | 4,063.25% | 553.06% |
| Granules India | -2.19% | 60.05% | 47.36% | 243.06% | 5,202.57% | 5,735.60% |
News Based Sentiment: Marksans Pharma vs Granules India
Marksans Pharma
News based Sentiment: NEGATIVE
September proved to be a difficult month for Marksans Pharma, with disappointing financial results and a significant decline in stock price overshadowing positive developments like regulatory approvals. The shift in institutional investment patterns and insider selling further contribute to a negative outlook, making this a crucial period for the company to demonstrate a turnaround strategy.
Granules India
News based Sentiment: MIXED
September presented a mixed bag for Granules India, with Q1 results showing revenue growth but declining profitability, countered by positive FDA approvals and continued analyst confidence. The combination of these factors creates a complex investment picture, making it a moderately significant month for the company.
Performance & Financial Health Analysis: Marksans Pharma vs Granules India
| Metric | MARKSANS | GRANULES |
|---|---|---|
| Market Information | ||
| Market Cap | ₹77.77B | ₹139.00B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 814,434 | 1,056,816 |
| 90 Day Avg. Volume | 1,028,523 | 2,159,367 |
| Last Close | ₹166.53 | ₹557.30 |
| 52 Week Range | ₹162.51 - ₹358.70 | ₹422.00 - ₹628.00 |
| % from 52W High | -53.57% | -11.26% |
| All-Time High | ₹358.70 (Dec 02, 2024) | ₹721.00 (Aug 26, 2024) |
| % from All-Time High | -53.57% | -22.70% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.05% | 0.03% |
| Quarterly Earnings Growth | -0.34% | -0.16% |
| Financial Health | ||
| Profit Margin (TTM) | 0.13% | 0.11% |
| Operating Margin (TTM) | 0.12% | 0.15% |
| Return on Equity (TTM) | 0.15% | 0.14% |
| Debt to Equity (MRQ) | 12.93 | 39.15 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹54.44 | ₹153.19 |
| Cash per Share (MRQ) | ₹15.58 | ₹19.34 |
| Operating Cash Flow (TTM) | ₹2.42B | ₹7.56B |
| Levered Free Cash Flow (TTM) | ₹3.81B | ₹5.02B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.62% | 0.30% |
| Last 12-Month Dividend | ₹1.40 | ₹1.50 |
Valuation & Enterprise Metrics Analysis: Marksans Pharma vs Granules India
| Metric | MARKSANS | GRANULES |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 21.54 | 27.57 |
| Forward P/E | 13.96 | 19.34 |
| PEG Ratio | -0.63 | -1.67 |
| Price to Sales (TTM) | 2.85 | 2.93 |
| Price to Book (MRQ) | 3.06 | 3.55 |
| Market Capitalization | ||
| Market Capitalization | ₹77.77B | ₹139.00B |
| Enterprise Value | ₹71.85B | ₹141.47B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.71 | 3.14 |
| Enterprise to EBITDA | 15.22 | 15.64 |
| Risk & Other Metrics | ||
| Beta | 1.17 | -0.14 |
| Book Value per Share (MRQ) | ₹54.44 | ₹153.19 |
Financial Statements Comparison: Marksans Pharma vs Granules India
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | MARKSANS | GRANULES |
|---|---|---|
| Revenue/Sales | ₹6.20B | ₹12.09B |
| Cost of Goods Sold | ₹2.62B | ₹4.25B |
| Gross Profit | ₹3.58B | ₹7.84B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹770.22M | ₹1.78B |
| EBITDA | ₹1.06B | ₹2.63B |
| Pre-Tax Income | ₹765.98M | ₹1.45B |
| Income Tax | ₹183.96M | ₹318.89M |
| Net Income (Profit) | ₹582.02M | ₹1.13B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | MARKSANS | GRANULES |
|---|---|---|
| Cash & Equivalents | ₹4.96B | ₹4.66B |
| Total Current Assets | ₹22.04B | ₹31.15B |
| Total Current Liabilities | ₹4.77B | ₹20.03B |
| Long-Term Debt | ₹2.63B | ₹4.71B |
| Total Shareholders Equity | ₹24.89B | ₹37.16B |
| Retained Earnings | ₹14.22B | ₹30.59B |
| Property, Plant & Equipment | ₹185.74M | ₹719.13M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | MARKSANS | GRANULES |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | MARKSANS | GRANULES |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 814,434 | 1,056,816 |
| Average Daily Volume (90 Day) | 1,028,523 | 2,159,367 |
| Shares Outstanding | 453.16M | 242.54M |
| Float Shares | 214.46M | 141.57M |
| % Held by Insiders | 0.46% | 0.40% |
| % Held by Institutions | 0.17% | 0.25% |
Dividend Analysis & Yield Comparison: Marksans Pharma vs Granules India
| Metric | MARKSANS | GRANULES |
|---|---|---|
| Last 12-Month Dividend | ₹1.40 | ₹1.50 |
| Last 12-Month Dividend Yield | 0.62% | 0.30% |
| 3-Year Avg Annual Dividend | ₹0.72 | ₹1.50 |
| 3-Year Avg Dividend Yield | 0.40% | 0.33% |
| 3-Year Total Dividends | ₹2.15 | ₹4.50 |
| Ex-Dividend Date | Aug 01, 2025 | Jul 31, 2025 |